In Brief: Orquest
This article was originally published in The Gray Sheet
Executive Summary
Orquest: Firm plans to commence U.S. clinical trials of its Healos bone grafting material for spinal fusion in early 1998 under an investigational device exemption submission by strategic development partner Spine-Tech, Michael Estes, president and CEO, states at the recent BancAmerica Robertson Stephens conference in New York City. Orquest also has a research agreement with Hoechst Marion Roussel for evaluation of Healos with Hoechst growth factors. The privately held, Mountain View, California firm is also preparing for clinical trials of its Ossigel injectable product for accelerating the healing of fractures...